BP’s AbbVie ABBV Stock Holding History

BP’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-39,669	Closed	-$4.47M	–	9
2021 Q2	$4.47M	Sell	39,669 -116,227	-75%	-$13.1M	0.19%	108
2021 Q1	$16.9M	Sell	155,896 -34,036	-18%	-$3.64M	0.59%	54
2020 Q4	$20.3M	Buy	189,932 +53,779	+39%	+$5.17M	0.62%	49
2020 Q3	$11.9M	Sell	136,153 -90,847	-40%	-$8.55M	0.29%	92
2020 Q2	$22.3M	Buy	227,000 +29,000	+15%	+$2.55M	0.81%	18
2020 Q1	$15M	Sell	198,000 -18,000	-8%	-$1.53M	0.64%	35
2019 Q4	$19.1M	Buy	216,000 +65,000	+43%	+$5.4M	0.64%	35
2019 Q3	$11.4M	Hold	151,000	–	–	0.42%	51
2019 Q2	$11M	Sell	151,000 -2,000	-1%	-$157K	0.41%	58
2019 Q1	$12.3M	Sell	153,000 -9,000	-6%	-$736K	0.48%	52
2018 Q4	$14.9M	Sell	162,000 -39,000	-19%	-$3.43M	0.62%	36
2018 Q3	$19M	Hold	201,000	–	–	0.58%	39
2018 Q2	$18.6M	Sell	201,000 -16,000	-7%	-$1.56M	0.6%	36
2018 Q1	$20.5M	Buy	217,000 +32,000	+17%	+$3.52M	0.75%	25
2017 Q4	$17.9M	Sell	185,000 -2,354	-1%	-$222K	0.64%	34
2017 Q3	$16.6M	Buy	187,354 +2,354	+1%	+$179K	0.59%	42
2017 Q2	$13.4M	Hold	185,000	–	–	0.49%	49
2017 Q1	$12.1M	Buy	185,000 +27,000	+17%	+$1.7M	0.46%	58
2016 Q4	$9.89M	Sell	158,000 -49,000	-24%	-$2.99M	0.37%	66
2016 Q3	$13.1M	Hold	207,000	–	–	0.5%	49
2016 Q2	$12.8M	Buy	207,000 +12,000	+6%	+$731K	0.51%	55
2016 Q1	$11.1M	Hold	195,000	–	–	0.45%	70
2015 Q4	$11.5M	Hold	195,000	–	–	0.47%	64
2015 Q3	$10.6M	Sell	195,000 -17,000	-8%	-$1.11M	0.48%	71
2015 Q2	$14.2M	Sell	212,000 -17,000	-7%	-$1.11M	0.54%	56
2015 Q1	$13.4M	Sell	229,000 -20,000	-8%	-$1.21M	0.43%	69
2014 Q4	$16.3M	Buy	249,000 +50,000	+25%	+$3.15M	0.41%	57
2014 Q3	$11.5M	Sell	199,000 -46,000	-19%	-$2.55M	0.33%	70
2014 Q2	$13.8M	Hold	245,000	–	–	0.44%	44
2014 Q1	$12.6M	Buy	245,000 +75,000	+44%	+$3.79M	0.42%	49
2013 Q4	$8.98M	Hold	170,000	–	–	0.33%	92
2013 Q3	$7.61M	Sell	170,000 -90,000	-35%	-$3.99M	0.45%	99
2013 Q2	$10.8M	Buy	+260,000	New	+$11.4M	0.65%	65

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BP's ABBV Position: Q3 2021 in Review

BP sold out of AbbVie (ABBV) in Q3 2021, closing a stake of 39,669 shares — an estimated $4.47M sold.

BP first reported a position in ABBV in Q2 2013 and held it in 33 quarters. The position peaked at $22.3M in Q2 2020. 2,654 funds tracked by Wall St. Rank hold ABBV as of Q3 2021.

BP reported no remaining AbbVie position as of Q3 2021 after selling out during the quarter.
BP sold 39,669 AbbVie shares in Q3 2021, an estimated $4.47M.
BP first reported a position in AbbVie in Q2 2013 and held it in 33 quarters.
BP's AbbVie position peaked at $22.3M in Q2 2020.
2,654 funds tracked by Wall St. Rank held AbbVie as of Q3 2021.

Based on BP's 13F filing for Q3 2021, filed 10 Nov 2021.